Concepedia

Author

Pia Roering

University of TurkuORCID

Also Known As

P. Roering, Pia Roering

15

Publications

307

Citations

8

H-Index

20

Concepts

All Affiliations

University of TurkuTurku University HospitalUniversity of HelsinkiTampere University Hospital
PR

About

Pia Roering is an author at University of Turku specializing in pathology, medicine, and ovarian cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

108

2

Pathology

4

4

108

3

Cell Biology

2

2

39

4

Obstetrics

2

2

35

5

Surgical Oncology

1

1

16

Pia Roering

×

8

Publications

300

Citations

8

H-Index

YearCitations

A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients

Manuela Tumiati, Sakari Hietanen, Johanna Hynninen,

Clinical Cancer Research

2018

112

18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer

Tuulia Vallius, Anniina Peter, Annika Auranen,

Gynecologic Oncology

2015

53

ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors

Katja Kaipio, Ping Chen, Pia Roering,

The Journal of Pathology

2019

53

Snorc is a novel cartilage specific small membrane proteoglycan expressed in differentiating and articular chondrocytes

Jussi Heinonen, Hanna Taipaleenmäki, Pia Roering,

Osteoarthritis and Cartilage

2011

20

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker

Laura Lehtinen, Pia Vesterkvist, Pia Roering,

PLoS ONE

2016

19

Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer

Tuulia Vallius, Johanna Hynninen, Annika Auranen,

Tumor Biology

2017

16

Open Source Infrastructure for Health Care Data Integration and Machine Learning Analyses

Veli‐Matti Isoviita, Liina Salminen, Jimmy C. Azar,

JCO Clinical Cancer Informatics

2019

16

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status

Pia Roering, Arafat Siddiqui, Vanina D. Heuser,

Frontiers in Oncology

2022

11

Page 1